Morvus Technology (United Kingdom) a preclinical-stage pharmaceutical company focused on prodrug and anti-angiogenic oncology approaches, closed a $3.3M Series A financing. Participants were not identified.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb